Neurotune AG   Report issue

For profit Phase 2
Founded: Zurich Switzerland (2005)
Status: Left NME R&D (2017)

Organization Overview

First Clinical Trial
2009
NCT01135251
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

dimiracetam (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 2)

HIV Infections (Phase 2)

Immunologic Deficiency Syndromes (Phase 2)

Peripheral Nervous System Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1